REMS Programs: Five Trends To Watch
This article was originally published in RPM Report
As FDA’s explicit authority to require drug safety and education programs approaches its second anniversary in mid-September 2009, some very distinct trends and issues are emerging for all NDA and BLA applicants. McKesson Specialty Care Solutions is positioned directly in the risk management and distribution controls space where the new REMS post-marketing programs exist. Here are someobservations from McKesson on the developing skills and operational issues associated with designing successful REMS programs.
You may also be interested in...
FDA has been perceived by drug developers as a regulator obsessed with drug safety. But recent cases show serious safety concerns aren’t holding back new products: efficacy has been the deciding factor for approval.
The first stage of REMS implementation from March 2008 until December 2009 was relatively easy. FDA and drug sponsors leaqrned how to adapt existing communications programs and techniques to deliver new safety messages. Now both the agency and the sponsors are moving into new territory: evaluating REMS. Both are grappling with the challenge of how to show that programs are working.